Indaptus Therapeutics, INC DEF 14A proxy statements

Indaptus Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026, to be held virtually, with key proposals including director elections and the approval of a new equity incentive plan.

Indaptus Therapeutics calls a Special Meeting to approve a significant capital raise, board changes, and corporate governance amendments crucial for its future strategic direction and Nasdaq compliance.

Indaptus Therapeutics, Inc. is convening a Special Meeting of Stockholders on July 25, 2025, to seek approval for the issuance of common stock underlying convertible notes and warrants from a recently closed and ongoing private placement, including participation by its CEO, to comply with Nasdaq listing rules.

Indaptus Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Indaptus Therapeutics is holding its annual meeting on June 10, 2025, to vote on director elections, auditor ratification, executive compensation, and a potential reverse stock split.

Indaptus Therapeutics, Inc. files a definitive proxy statement with the SEC.

Indaptus Therapeutics is holding its annual meeting on June 6, 2024, to vote on the election of directors, ratification of its auditor, and an amendment to its stock incentive plan.